Scientists have discovered that the shingles vaccine Shingrix, developed by GSK Plc (NYSE:GSK), may reduce the risk of dementia, a finding that could significantly impact public health. The research, published in Nature Medicine, showed that individuals vaccinated with Shingrix lived an average of 164 days longer without a dementia diagnosis compared to those who received the older Zostavax vaccine. Related: GSK Says Its Blockbuster Shingles Vaccine Shows High Efficacy Even After 10 Years The study, led by Maxime Taquet, a clinical lecturer in Oxford University’s psychiatry department, analyzed data from 200,000 people. Taquet stated the findings were “convincing” and called for further research to validate the hypothesis that shingles vaccination might ...